Compounded Tirzepatide Compounded Semaglutide Same active ingredient as Ozempic & Wegovy GLP-1 receptor agonist (single target) Average weight loss: ~15% of body weight Once-weekly subcutaneous injection Gradual dose titration over 48 weeks Well-studied safety profile Good starting option for most patients Compounded Tirzepatide Same active ingredient as Mounjaro & Zepbound Dual GLP-1 + GIP receptor agonist Average weight loss: up to 21% of body weight Once-weekly subcutaneous injection Gradual dose titration over 48 weeks Additional blood sugar regulation via GIP pathway May be more effective for patients with insulin resistance Not sure which is right for you
Resources like SeekPeptides have documented these patterns extensively, providing researchers with tools to navigate nutrient management during GLP-1 therapy
Do not take them if you or your family have a history of certain thyroid cancers
If you are ready to explore a targeted approach to fat loss, our team is here to help
Patients, investigators, and several nurses were blinded to the treatment arms, except for some unblinded study nurses, who injected the trial medication
Long-term, lower level exposure results in cadmium accumulation in the kidneys and thyroid gland, and can contribute to thyroid issues, kidney disease, infertility, uterine fibroids, and other reproductive tract diseases if the build-up is high enough
